Frank Stokes Sells 6,001 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) CFO Frank Stokes sold 6,001 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $27.98, for a total value of $167,907.98. Following the completion of the transaction, the chief financial officer owned 60,085 shares in the company, valued at $1,681,178.30. This represents a 9.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Frank Stokes also recently made the following trade(s):

• On Tuesday, March 3rd, Frank Stokes sold 7,000 shares of Castle Biosciences stock. The stock was sold at an average price of $27.44, for a total value of $192,080.00.

Castle Biosciences Price Performance

CSTL stock opened at $26.60 on Wednesday. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $44.28. The company has a quick ratio of 5.11, a current ratio of 5.26 and a debt-to-equity ratio of 0.02. The stock has a market cap of $790.82 million, a price-to-earnings ratio of -31.29 and a beta of 1.09. The business has a fifty day moving average of $35.42 and a two-hundred day moving average of $31.66.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.15. The business had revenue of $81.88 million for the quarter, compared to analyst estimates of $81.19 million. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%. As a group, research analysts anticipate that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on CSTL shares. Lake Street Capital increased their target price on shares of Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Canaccord Genuity Group boosted their price target on shares of Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Morgan Stanley upgraded shares of Castle Biosciences to a “buy” rating in a report on Monday, March 2nd. KeyCorp reiterated an “overweight” rating and issued a $50.00 target price on shares of Castle Biosciences in a report on Thursday, January 29th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Castle Biosciences in a research report on Monday, December 29th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Castle Biosciences has a consensus rating of “Moderate Buy” and an average target price of $47.57.

Institutional Investors Weigh In On Castle Biosciences

Large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd raised its position in Castle Biosciences by 188.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,099 shares of the company’s stock valued at $82,000 after purchasing an additional 1,371 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Castle Biosciences by 142.6% in the 4th quarter. Invesco Ltd. now owns 135,461 shares of the company’s stock valued at $5,269,000 after buying an additional 79,621 shares during the period. Mackenzie Financial Corp grew its position in shares of Castle Biosciences by 54.2% during the fourth quarter. Mackenzie Financial Corp now owns 37,317 shares of the company’s stock worth $1,464,000 after buying an additional 13,113 shares in the last quarter. Empowered Funds LLC increased its stake in shares of Castle Biosciences by 24.2% during the fourth quarter. Empowered Funds LLC now owns 121,920 shares of the company’s stock worth $4,743,000 after buying an additional 23,740 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Castle Biosciences during the fourth quarter worth approximately $861,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences News Summary

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: New clinical data bolstering DecisionDx‑Melanoma: a large prospective multicenter study presented at SSO 2026 reported just 2.6% nodal positivity for patients the test predicts are <5% risk, supporting guideline guidance to avoid sentinel‑node biopsy in low‑risk patients — this validates the test’s clinical utility and could help adoption. DecisionDx Melanoma study
• Positive Sentiment: Recent quarterly results and analyst activity are supportive: the Feb. 26 quarter beat EPS expectations (‑$0.08 vs. est. ‑$0.23) and revenue roughly matched estimates; several firms raised price targets and maintain buy/outperform views — a fundamental backdrop that can undercut deeper selloffs. MarketBeat earnings & analyst note
• Neutral Sentiment: Institutional ownership is high (reported ~92.6%) with some funds adding shares in Q4, which can reduce float and increase stability, though it also concentrates risk. Institutional holdings detail
• Neutral Sentiment: Short‑interest reports in early March show anomalous “0 shares” / NaN values and a 0.0 days‑to‑cover metric — data likely erroneous or delayed, so current short‑interest impact is unclear. (No actionable short‑squeeze signal from these reports.)
• Negative Sentiment: Insider selling: CFO Frank Stokes sold 6,001 shares (avg ~$27.98) on March 5 (and sold 7,000 shares on March 3); Director G. Bradley Cole sold 7,403 shares (~$28.47). Multiple recent insider disposals can pressure sentiment and be interpreted as insiders taking profits. Insider trades report

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.